These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

470 related items for PubMed ID: 34197005

  • 1. Prevalence and impact of HLA and MICA allele mismatching on donor-specific antibodies induction in kidney transplant rejection.
    Romphruk AV, Simtong P, Suntornnipat J, Sudwilai Y, Cheunta S, Chan-On C, Leelayuwat C.
    Nephrology (Carlton); 2021 Oct; 26(10):833-841. PubMed ID: 34197005
    [Abstract] [Full Text] [Related]

  • 2. Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study.
    Senev A, Coemans M, Lerut E, Van Sandt V, Kerkhofs J, Daniëls L, Driessche MV, Compernolle V, Sprangers B, Van Loon E, Callemeyn J, Claas F, Tambur AR, Verbeke G, Kuypers D, Emonds MP, Naesens M.
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [Abstract] [Full Text] [Related]

  • 3. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N, Gozdowska J, Zagożdżon R.
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [Abstract] [Full Text] [Related]

  • 4. Major histocompatibility complex class I-related chain A allele mismatching, antibodies, and rejection in renal transplantation.
    Cox ST, Stephens HA, Fernando R, Karasu A, Harber M, Howie AJ, Powis S, Zou Y, Stastny P, Madrigal JA, Little AM.
    Hum Immunol; 2011 Oct; 72(10):827-34. PubMed ID: 21664940
    [Abstract] [Full Text] [Related]

  • 5. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D, Bach C, Staudner C, Böger CA, Bergler T, Banas B, Spriewald BM.
    Nephrol Dial Transplant; 2017 Apr 01; 32(4):730-737. PubMed ID: 28339671
    [Abstract] [Full Text] [Related]

  • 6. Clinical relevance of major histocompatibility complex class I chain-related molecule A (MICA) antibodies in live donor renal transplantation - Indian Experience.
    Baranwal AK, Bhat DK, Goswami S, Agarwal SK, Kaur G, Mehra N.
    Scand J Immunol; 2020 Nov 01; 92(5):e12923. PubMed ID: 32593197
    [Abstract] [Full Text] [Related]

  • 7. Deleterious Impact of Donor-Specific Anti-HLA Antibodies Toward HLA-Cw and HLA-DP in Kidney Transplantation.
    Bachelet T, Martinez C, Del Bello A, Couzi L, Kejji S, Guidicelli G, Lepreux S, Visentin J, Congy-Jolivet N, Rostaing L, Taupin JL, Kamar N, Merville P.
    Transplantation; 2016 Jan 01; 100(1):159-66. PubMed ID: 26262501
    [Abstract] [Full Text] [Related]

  • 8. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P, Jin J, Everly MJ, Lin C, Terasaki PI, Chen J.
    Clin Biochem; 2013 Oct 01; 46(15):1389-93. PubMed ID: 23726814
    [Abstract] [Full Text] [Related]

  • 9. HLA and MICA: targets of antibody-mediated rejection in heart transplantation.
    Zhang Q, Cecka JM, Gjertson DW, Ge P, Rose ML, Patel JK, Ardehali A, Kobashigawa JA, Fishbein MC, Reed EF.
    Transplantation; 2011 May 27; 91(10):1153-8. PubMed ID: 21544036
    [Abstract] [Full Text] [Related]

  • 10. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
    Almeshari K, Pall A, Chaballout A, Elgamal H, Almana H, Alzayer F, Abaalkhail N, Altalhi M.
    Clin Transpl; 2011 May 27; ():395-400. PubMed ID: 22755437
    [Abstract] [Full Text] [Related]

  • 11. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM, Patel SJ, Burns KM, Dilioglou S, Gaber LW, Knight RJ, Gaber AO, Land GA.
    Clin Transpl; 2011 May 27; ():351-8. PubMed ID: 22755430
    [Abstract] [Full Text] [Related]

  • 12. Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients.
    Pavlova YA, Malek I, Honsova E, Netuka I, Sochman J, Lodererova A, Kolesar L, Striz I, Skibova J, Slavcev A.
    Tissue Antigens; 2010 Nov 27; 76(5):380-6. PubMed ID: 20604893
    [Abstract] [Full Text] [Related]

  • 13. Acute Antibody-Mediated Rejection in Presence of MICA-DSA and Successful Renal Re-Transplant with Negative-MICA Virtual Crossmatch.
    Ming Y, Hu J, Luo Q, Ding X, Luo W, Zhuang Q, Zou Y.
    PLoS One; 2015 Nov 27; 10(5):e0127861. PubMed ID: 26024219
    [Abstract] [Full Text] [Related]

  • 14. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J, Xue W, Qing X, Jing X, Hou J, Tian X, Guo Q, He X, Cai J.
    Clin Transpl; 2014 Nov 27; ():223-30. PubMed ID: 26281149
    [Abstract] [Full Text] [Related]

  • 15. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D, Lee J, Schwartz JE, Friedlander R, Aull M, Muthukumar T, Campbell S, Epstein D, Seshan SV, Kapur S, Sharma VK, Suthanthiran M, Dadhania D.
    Transplantation; 2015 Jun 27; 99(6):1156-64. PubMed ID: 25629531
    [Abstract] [Full Text] [Related]

  • 16. Analysis of Luminex-based Algorithms to Define Unacceptable HLA Antibodies in CDC-crossmatch Negative Kidney Transplant Recipients.
    Zecher D, Bach C, Preiss A, Staudner C, Utpatel K, Evert M, Jung B, Bergler T, Böger CA, Spriewald BM, Banas B.
    Transplantation; 2018 Jun 27; 102(6):969-977. PubMed ID: 29470350
    [Abstract] [Full Text] [Related]

  • 17. Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation.
    Nath DS, Angaswamy N, Basha HI, Phelan D, Moazami N, Ewald GA, Mohanakumar T.
    Hum Immunol; 2010 Dec 27; 71(12):1191-6. PubMed ID: 20868717
    [Abstract] [Full Text] [Related]

  • 18. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G, Furst D, Mytilineos J, Pourmand G, Amirzargar AA.
    Transpl Immunol; 2012 Mar 27; 26(2-3):81-7. PubMed ID: 22182633
    [Abstract] [Full Text] [Related]

  • 19. Class II HLA Eplet Mismatch Is a Risk Factor for De Novo Donor-Specific Antibody Development and Antibody-mediated Rejection in Kidney Transplantation Recipients.
    Kishikawa H, Kinoshita T, Hashimoto M, Fukae S, Taniguchi A, Yamanaka K, Nakagawa M, Nishimura K.
    Transplant Proc; 2018 Oct 27; 50(8):2388-2391. PubMed ID: 30316363
    [Abstract] [Full Text] [Related]

  • 20. [Relationship of distribution frequency of HLA antigen/antibody and PIRCHE score with DSA production and AMR occurrence].
    Zheng J, Kuang PD, Zhang Y, Zhao Q, He XL, Ding XM, Xue WJ.
    Zhonghua Yi Xue Za Zhi; 2019 Mar 26; 99(12):901-906. PubMed ID: 30917438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.